Clik here to view.
ARTMSとテリックス・ファーマシューティカルズが固体ターゲットからサイクロトロンで製造した68Gaを使用してPSMA-11を成功裏に製造と発表
加ブリティッシュコロンビア州バーナビー & インディアナポリス （ビジネスワイヤ） — ARTMS Inc.（「ARTMS」）とテリックス・ファーマシューティカルズ・リミテッド（ASX: TLX、「テリックス」）は、ARTMS専有のQuantum Irradiation...
View ArticleClik here to view.
ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S....
View ArticleClik here to view.
ADDING MULTIMEDIA — ENHERTU® Approved in the U.S. for the Treatment of...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S....
View ArticleClik here to view.
EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc. ( “Company”, or “EdiGene”), today announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved...
View ArticleClik here to view.
ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic...
TOKYO & MUNICH Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (trastuzumab deruxtecan) has been granted conditional approval in the European Union (EU) as...
View ArticleClik here to view.
ARTMS和Isotopia Molecular Imaging宣布成功通过QUANTM Irradiation...
不列颠哥伦比亚省本拿比和以色列佩塔提科瓦 (美国商业资讯)– ARTMS Inc. (ARTMS)和Isotopia Molecular Imaging (Isotopia)欣然宣布，成功通过ARTMS拥有专利的Quantum Irradiation System™ (QIS™)固态靶材系统，用超过2居里(Ci)的经由回旋加速器生产的镓68...
View ArticleClik here to view.
ARTMSとアイソトピア・モレキュラー・イメージングが、QUANTM Irradiation...
加ブリティッシュコロンビア州バーナビー & イスラエル・ペタクチクヴァ （ビジネスワイヤ） — ARTMS Inc.（ARTMS）とアイソトピア・モレキュラー・イメージング（アイソトピア）は、ARTMSの専有的なQuantum Irradiation System™（QIS™）固体ターゲットシステムを利用してサイクロトロンで製造したガリウム68（68Ga）を2...
View ArticleClik here to view.
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trial for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SHA: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics...
View ArticleClik here to view.
Qurient Enrolls First Patient in Q702 U.S. Phase 1 Study
SEONGNAM-SI, Korea Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the first patient was dosed in the Q702 phase 1 study being conducted in the...
View ArticleClik here to view.
Genetron Health to Release Thirteen Research Findings at 21st World...
BEIJING Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early...
View ArticleClik here to view.
BeiGene Announces Positive Topline Results for Global Phase 3 Trial of...
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today...
View ArticleClik here to view.
Ultimovacs Announces NIPU Trial Design Poster Presented at World Conference...
OSLO, Norway Ultimovacs ASA (“Ultimovacs”, ticker ULTI), today announced that the lead investigator of the Company’s NIPU Phase II clinical trial, Åslaug Helland from Oslo University Hospital, has...
View ArticleClik here to view.
Takeda Presents Positive Results For Mobocertinib in Patients with EGFR...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data from the Phase 1/2 trial of mobocertinib (TAK-788) orally...
View ArticleClik here to view.
ImmunoScape Establishes Scientific Advisory Board of Distinguished Immunology...
SINGAPORE & SAN DIEGO ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced the formation of its...
View ArticleClik here to view.
Bio-Thera Solutions Announces FDA Accepts Biologics License Application for...
GUANGZHOU, China Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License...
View ArticleClik here to view.
武田薬品、プラチナ製剤ベースの化学療法歴を有するEGFRエクソン20挿入変異陽性mNSCLC患者でのモボセルチニブの良好な結果を発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Exelixis and Adagene Enter into Collaboration and License Agreement to...
ALAMEDA, Calif., SAN FRANCISCO & SUZHOU, China Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license agreement under which Exelixis will utilize Adagene’s...
View ArticleClik here to view.
Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co.,...
CAMBRIDGE, Mass. Ribon Therapeutics, a clinical stage oncology company developing therapeutics targeting stress support pathways, today announced it has entered into an exclusive license agreement...
View ArticleClik here to view.
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with...
TOKYO & MUNICH & BASKING RIDGE, N.J. & NASHVILLE, Tenn. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute (Sarah Cannon) announced today...
View ArticleClik here to view.
造血器腫瘍遺伝子パネル検査に関する開発および商業化契約締結について
東京 （ビジネスワイヤ） — 大塚製薬株式会社（本社：東京都、代表取締役社長：井上眞、以下「大塚製薬」）と次世代シークエンサーの世界トップ企業であるIllumina, Inc.（本社：米国カリフォルニア州サンディエゴ、CEO：Francis...
View Article